Wire · opportunities
ESMO: Bristol Myers CMO touts '5 out of 5' positive phase 3 trials for bispecific ADC iza-bren
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
Bristol Myers Squibb's bispecific antibody-drug conjugate izalontamab brengitecan (iza-bren) achieved five out of five positive phase 3 trial results in China, showing significant progression-free survival improvements in EGFR-mutant non-small cell lung cancer and HR-positive, HER2-negative breast cancer. While global trials are starting, the company is still assessing expansion plans for some indications amid competitive treatment landscapes.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must consider how five successful phase 3 trials in China open a commercial opportunity in Asian cancer markets while global efforts are still catching up. Competitive data means you need to act fast to define your drug's placement before others dominate in breast and lung cancer therapies.
◆ Coverage
1 source · 26 Oct 2026
◆ Related on Wire
◆ Topics